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Abstract
Background: HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects.
We evaluated the influence of rifampicin cotreatment, efavirenz pharmacokinetics and pharmacogenetics on
neuropsychiatric disorders in Ugandan HIV patients with or without tuberculosis coinfection.
Methods: 197 treatment naïve Ugandan HIV patients, of whom 138 were TB co-infected, enrolled prospectively and
received efavirenz based HAART. TB-HIV confected patients received concomitant rifampicin based anti-TB therapy.
Genotypes for CYP2B6 (*6, *11), CYP3A5 (*3, *6, *7), ABCB1 (c.3435C>T and c.4036 A/G rs3842), CYP2A6 (*9, *17) and
NR1I3 rs3003596 T/C were determined. Efavirenz plasma concentrations were serially quantified at 3rd day, 1st, 2nd,
4th, 6th, 8th and 12th weeks during therapy. Efavirenz neuropsychiatric symptoms were evaluated in terms of sleep
disorders, hallucinations and cognitive effects at baseline, at two and twelve weeks of efavirenz treatment using a
modified Mini Mental State Examination (MMSE) score.
Results: During the first twelve weeks of ART, 73.6% of the patients experienced at least one efavirenz related
neuropsychiatric symptom. Commonest symptoms experienced were sleep disorders 60.5% (n=124) and
hallucination 30.7% (n=63). Neuropsychiatric symptoms during HAART were significantly predicted by efavirenz
plasma concentrations consistently. Rifampicin cotreatment reduced plasma efavirenz concentrations significantly
only during the first week but not afterwards. There was no significant difference in the incidence of
neuropsychiatric symptoms between patients receiving efavirenz with or without rifampicin cotreatment. CYP2B6*6
and ABCB1 c.4036 A/G genotype significantly predicted efavirenz concentrations. The tendency of CYP2B6*6
genotype association with higher incidence of having vivid dream (p=0.05), insomnia (p=0.19) and tactile
hallucination (p=0.09) was observed mainly at week-2.
Conclusions: Efavirenz related neuropsychiatric symptoms are common among Ugandan HIV patients receiving
ART and is mainly predicted by higher efavirenz plasma concentrations and CYP2B6 genotype but not by rifampicin
based anti-TB co-treatment.
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Background
The severity of HIV-associated neurocognitive disorders
has been reduced in the era of HAART but neurological
effects due to antiretroviral toxicity have become an
increasing burden in HIV-infected patients [1,2]. Despite
the indisputable benefits, concerns with the adverse ef-
fects of efavirenz use particularly neuropsychiatric symp-
toms are well recognized [3-5]. Efavirenz crosses the
blood–brain barrier attaining cerebral spinal fluid con-
centrations 0.5 to 1.2% of its corresponding plasma con-
centrations, reaching therapeutic concentrations in brain
[6,7]. Clinical studies have reported high rates of neuro-
psychiatric side effects including vivid dreams, insomnia
and mood changes in > 50% of the patients who initiate
efavirenz [8-12]. Although most CNS symptoms are
mild, up to one-fifth of all individuals commencing
efavirenz-containing regimen discontinue the drug and
switch therapy primarily because of unbearable neuro-
toxicity, minimizing further therapeutic options [13].
Efavirenz is primarily metabolized to 8-hydroxyefavirenz
mainly by CYP2B6 and to a lesser extent by CYP3A
[14,15]. Importance of CYP3A in mediating efavirenz me-
tabolism particularly in subjects with CYP2B6 slow
metabolizers is described recently [16]. CYP2A6 mediated
7-hydroxylation accounts about 23% of total efavirenz me-
tabolism [15]. P-glycoprotein, encoded by ABCB1, is the
major efflux transporter at the blood–brain barrier that
limits entry into the CNS for a large number of drugs, and
probably contributes to patient-to-patient variability in re-
sponse to CNS pharmacotherapy [17]. Although in vitro
and animal studies report that P-glycoprotein is not the
main cellular transporter protein for efavirenz [18], several
studies in African HIV patients reported association of
genetic variation in ABCB1 with efavirenz plasma/intra-
cellular concentrations and/or treatment outcome. Associ-
ations between ABCB1 c.4036A>G with higher plasma
efavirenz concentrations in Ugandan HIV patients was
first reported by our group [19], a finding latter confirmed
in South African [20], Ethiopian and Tanzanians [21] as
well as in other non-African populations [22]. Association
of ABCB1 c.3435C>T variation with CD4-cell recovery
after efavirenz therapy initiation is also reported [22,23].
Accordingly P-glycoprotein may have a role in efavirenz
cellular transport or alternatively the functional genetic
variants in ABCB1 might be in strong linkage disequilib-
rium with other SNPs located in another gene relevant for
efavirenz disposition and hence may serve as tag SNP. All
enzymes involved in efavirenz disposition including
ABCB1 are inducible by efavirenz mainly via the activation
of human constitutive androstane receptor (hCAR),
encoded by NR1I3 gene [24]. Several studies reported as-
sociation of genetic variation in CYP2B6, CYP3A5,
CYP2A6, ABCB1 and NR1I3 with plasma efavirenz con-
centration in HIV patients is reported [16,19,20,25,26].
However effects of pharmacogenetic variations on suscep-
tibility to efavirenz induced neuropsychiatric disorders
particularly in Sub-Saharan African HIV patients remains
to be investigated well.
Mid-dose or trough efavirenz plasma concentrations
<1 μg/mL is reported to increase the risk of virologic
failure, while concentrations > 4 μg/mL increased likeli-
hood of developing neuropsychiatric side effects in HIV-
infected patients [27,28]. Rifampicin, a potent inducer of
drug metabolizing enzymes and transporter proteins, re-
duces efavirenz plasma concentration but the extent of
drug interaction varies between populations and is
influenced by CYP2B6 genotype [29-33]. Treatment suc-
cess with efavirenz therefore requires maintenance of an
optimal plasma concentration ensuring a balance be-
tween neuropsychiatric toxicity and possible treatment
failure [34]. Complex drug interactions might also con-
tribute to CNS symptoms and this might be particularly
relevant in patients being treated with efavirenz-
containing regimens. CNS side effects associated with
other first line anti tuberculosis drugs such as isoniazid
[35-38] may further complicate TB-HIV co-treatment.
Clinical studies reported increased levels of efavirenz
and higher rates of neuropsychiatric disorders particu-
larly in patients of African origin [39,40]. A recent study
reported association of black ethnicity and CYP2B6
516TT genotype with early discontinuation of efavirenz-
containing regimens [41]. The defective CYP2B6
G516Tvariant allele, which impairs efavirenz metabolism,
is common in African populations [16,19] and its impact
on efavirenz plasma concentrations may surpass the
counter effect of rifampicin co-administration [31-33].
Variations in efavirenz tolerability during rifampicin
treatment may therefore be attributed to pharmacogene-
tic factors that influence neuropsychiatric toxicity during
TB-HIV co-treatment.
While the role of pharmacogenetics in efavirenz – rifam-
picin pharmacokinetic interactions has been substantively
investigated, the possibly compounded neuropsychiatric
toxicities during co- treatment with the two drugs have
not been adequately described. Because of high prevalence
of HIV, efavirenz based HAART is widely used in Sub-
Saharan Africa, but data on the incidence and risk factors
of efavirenz associated neuropsychiatric symptoms are
limited [42,43]. African populations display wide genetic
heterogeneity and hence data from one geographic region
may not be extrapolated directly to others with in the con-
tinent [44,45] and hence more studies are required to
evaluate the incidence and risk factors of efavirenz related
neuropsychiatric disorders. In the present study we evalu-
ated pharmacogenetic and pharmacokinetic aspects of
efavirenz associated Neuropsychological symptoms in
Ugandan HIV patients receiving efavirenz based HAART
with or without rifampicin based anti-tuberculosis
Mukonzo et al. BMC Infectious Diseases 2013, 13:261 Page 2 of 11
http://www.biomedcentral.com/1471-2334/13/261
therapy. The primary objective was to evaluate the inci-
dence, timing, predictors and type of efavirenz based
HAART associated neuropsychiatric disorders in Ugandan
HIV patients with or without tuberculosis coinfection.
Our secondary objectives were to evaluate 1) Effect of ri-
fampicin co-treatment on the incidence of efavirenz based
HAART associated neuropsychiatric disorders 2) Associ-
ation between neuropsychiatric disorders and efavirenz
plasma concentrations monitored on day 3 and at 1, 2, 4,
6, 8 and 12 weeks during therapy. 3) Associations of
pharmacogenetic variations in CYP2B6, CYP3A5, CYP2A6,
ABCB1 and NR1I3 with susceptibility to efavirenz induced
neuropsychiatric disorders.
Methods
Newly diagnosed ART naïve HIV patients with or without
tuberculosis coinfection attending the HIV/TB or HIV
clinic at Mulago and Butabika National referral Hospitals
in Kampala Uganda were recruited and enrolled into the
study during the years 2008 to 2009. HIV only infected
patients received efavirenz based HAART as per the na-
tional treatment guideline. HIV-TB coinfected patients re-
ceived rifampicin based anti-TB regimen for 6 months
under direct observe therapy (2 months ethambutol / iso-
niazid / rifampicin /pyrazinamide followed by 4 months of
isoniazid and rifampicin combination therapy) initiated 2–
8 weeks before ART. Adherence to ART was evaluated
based on self-report. Fifty-nine of the patients were HIV
infected without TB co-infection and received ART ther-
apy only. CD4 analysis was performed to ensure eligibility
for HIV treatment. Only patients eligible for efavirenz
according to the national treatment guidelines at enrol-
ment were recruited into the study. All eligible patients
were treated, for HIV, with efavirenz 600mgs daily in com-
bination with zidovudine and lamivudine and followed up
for at least 6 months. Blood samples for genotyping were
collected at enrollment while mid-dose efavirenz plasma
concentration samples for the study were collected during
follow-up visits. Patients were evaluated for central
neuropsychiatric disorders at baseline and on follow-up
visits at weeks 2 and 12. The study was approved by
local ethical committees at Mulago and Butabika hospi-
tals and the Uganda National Council for Science and
Technology. A written informed consent was obtained
from each study participant.
Efavirenz pharmacokinetic analysis
Blood samples were collected into EDTA tubes at enroll-
ment and at 11 to 18 hours post dose on day 3 and at
weeks 1, 2, 4, 6, 8 and 12. Plasma was prepared from
blood samples by centrifugation at 3000 rpm for 10 min
and stored at -70°C until HPLC analysis was performed.
Plasma efavirenz was determined by reverse phase
HPLC with UV-detection as previously described [19].
The HPLC machine, Agilent series 1100, consisting of
column compartment G1316A, Degasser G132A, Quat
pump G1311A, and an auto-sampler ALS, G1329A, and
G1315B diode array detector was used. The column
used was Ace3C18, 3 μm 50×30 mm (Advanced Chro-
matography Technologies, Aberdeen, Scotland). The
standard used was efavirenz (99.9), supplied by the
WHO Collaborating center for chemical reference sub-
stances through Apoteket AB Stockholm, Sweden. The
retention time for efavirenz was 2.42 minutes as
detected at UV–VIS 1, 210 nm, UV–VIS 2, 220 nm.
Within-day coefficient of variations was 3.2, 3.3 and 5.1
at concentrations of 2.0 μM (n=17), 8.0 μM (n=17), and
20 μM (n=16) respectively and between-day coefficient
of variation was 4.1 (n=50).
Genotyping
Genomic DNA was isolated from peripheral blood leuko-
cytes using QIAamp DNA Maxi Kit (QIAGEN GmbH.
Hilden. Germany). All participants were genotyped for
CYP2B6*6 and *11, CYP3A5*3,*6 and *7 and ABCB1
(3435CT and rs3842).Allelic discrimination reactions were
performed using TaqMan (Applied Biosystems, CA, USA)
genotyping assays: (C___7586657_20 for ABCB1 3435C>T,
C___7817765_60, for ABCB1 rs3842T>C, C__29560333_20,
for CYPB6 516G>T [CYP2B6*6 ], for CYP2B6 136A>G
[CYP2B6*11], C__26201809_30 for CYP3A5 6986A>G
[CYP3A5*3], C_16194070_10 for NR1I3 rs3003596T/C,
C_30634332_10 for CYP2A6 -48T>G [CYP2A6*9],
C_34816076_20 for CYP2A6 5065 G>A [CYP2A6*17],
C__30203950_10 for CYP3A5 14690G>A [CYP3A5*6])
and C__32287188_10 for CYP3A5 g.27131_27132insT
[CYP3A5*7] on ABI 7500 FAST (Applied Biosystems,
Foster City, CA). The final volume for each reaction
was 10μl, consisting of 2x TaqMan Universal PCR Master
Mix (Applied Biosystems, Foster City, CA, USA). 20 ×
drug metabolising genotype assay mix and 10 ng genomic
DNA. The PCR profile consisted of an initial step at 50°C
for 2 min and 50 cycles with 95°C for 10 minutes and 92°C
for 15 sec.
Neuropsychiatric symptom monitoring
Efavirenz neuropsychiatric effects were evaluated in
terms of sleep disorders, hallucinations and cognitive
effects at baseline, two and twelve weeks of efavirenz
treatment. The adjusted mini mental status evaluation
(MMSE) form that takes care of the possible differences
due to variations in the level of education and age differ-
ences [46] was supplemented with questions which were
used to assess sleep disorders and halucinations.
Assessment for sleep disorders was based on patient’s
experience of insomnia, vivid dreams and sleepwalking
as far as they could remember at baseline and during the
first 2 weeks and 2 to 12 weeks of ART initiation.
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Patients were declared to have experienced mild insom-
nia if they failed to fall asleep within 15 minutes of going
to bed, moderate insomnia if they went out of bed for
up to one hour as a result of failure to sleep and severe
insomnia if they went and stayed out of bed for more
than one hour because of failure to sleep. Assessment of
outcomes for both vivid dreams and sleepwalking were
yes or no as declared by study participants. Overall as-
sessment outcome for sleep disorder was no or yes for
patients that did not or suffered any form of insomnia
or experienced vivid dreams or sleep walking respec-
tively. Patients were also assessed for three forms of hal-
lucinations which included; auditory, visual and tactile
hallucinations. The assessment outcome was no or yes
for each form of hallucination and for hallucinations in
general if the patient reported experience of any of the
three forms. Patients were scored for cognition based
only upon their responses to relevant questions
according to the adjusted min mental status evaluation
(MMSE) form [46]. Adjusted MMSE scores >23 were
interpreted as normal while 20–23 and ≤19 were
interpreted mild to moderate and severe cognitive disor-
ders respectively. Overall, patients that either experi-
enced any new or severer forms of neuropsychiatric
symptoms following initiation of efavirenz were consid-
ered positive for the evaluation. For accuracy of data, a
trained psychiatric nurse under the supervision of a
physician administrated all neuropsychiatric assessment
forms while completeness of data was improved by gi-
ving patients telephone reminders of their neuropsychi-
atric evaluation visits 24 hours in advance.
Data analysis
Descriptive analysis was performed to determine the mean
and the standard deviation for continuous variables and
the percentages for categorical variables. Normality of
efavirenz concentration data was achieved through log10
transformation of all values. Comparison of proportion of
subjects with and without neuropsychiatric disorders be-
tween the two treatment groups, sex and genotype groups
were done using Chi-square test. Correction for multiple
testing was done using Bonferroni method. Comparisons
of efavirenz plasma concentration between patients with
or without neuropsychiatric disorders as well as between
the two treatment groups (presence or absence of rifam-
picin cotreatment) were done using independent sample
T-test. Levene’s test was applied to determine variance
homogeneity. Multivariate analyses were conducted using
logistic regression and linear mixed model to identify fac-
tors associated with neuropsychiatric symptoms. Efavirenz
concentration, rifampicin treatment status and sex were
included as predictors. Variables with p value < 0.3 in the
Univariate analysis were included in the multivariate
logistic regression with backward stepwise conditional
elimination. Multivariate linear mixed effects model was
used to control for the multiple repeated measurements
contributed by the same patient at different time points.
The dependent variable neuropsychiatric toxicity was code
as yes =1 and no =0. Interaction test was performed,
multi-collinearity problem checked and Hosmer and
Lemeshaw test employed to examine the overall fitness of
the model. Path analysis was performed to assess geno-
types, rifampicin co-treatment and efavirenz concentra-
tions as predictors for drug- associated neuropsychiatric
toxicity. The level of statistical significance was specified
at 0.05 for all tests. Statistical analysis was performed
using IBM® SPSS® statistics software version 20.
Results
A total of 197 subjects participated in the study. Fifty-
nine of them were HIV patients treated with efavirenz
based HAART only. The remaining 138 were HIV-TB
confected patients treated with both efavirenz based
HAART and rifampicin based anti-tuberculosis drugs.
Demographic characteristics of study participants, mea-
sures of HIV disease and frequency of neuropsychiatric
symptoms at baseline are presented in Table 1. Neuro-
psychiatric disorder was evaluated in 100%, 96% (98.6%
for rifampicin and 91.5% for none rifampicin treatment
groups) and 89.9% (94.9% for rifampicin and 80.5% for
none rifampicin treatment groups) at baseline, week 2
and week 12 respectively.
Neuropsychiatric disorders
Neuropsychiatric symptoms were overall reported in
31% of patients at ART initiation, the majority (74%) of
whom exhibited a cognition disorder: MMSE score <19.
Baseline neuropsychiatric symptoms did not significantly
differ between HIV patients co-infected with or without
TB except for cognitive disorder whose incidence was
higher among patients co-infected with TB (Table 1).
During the initial twelve weeks of efavirenz treatment,
73.6% (n = 142) of the participants experienced at least
one efavirenz related neuropsychiatric symptom. The
commonest form of neuropsychiatric disorder exhibited
was sleep disorders 60.5% (n= 124), followed by hallu-
cination 30.7% (n = 63). Cognition improved with
efavirenz based antiretroviral therapy, with the number
of patients scored <19 on the MMSE being reduced
from 46 (23.3%) at ART initiation to 22 (10.7%) at twelve
weeks of treatment. The incidence of neuropsychiatric
toxicity did not differ between the rifampicin and non-
rifampicin treatment groups (p=0.70). Even at week two,
when most neuropsychiatric symptoms were reported,
no significant differences were observed between the
two treatment groups.
Vivid dreams, the commonest sleep disorder symptom
was experienced by 93% (n = 115) of those that suffered
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any form of efavirenz associated sleep disorder. All pa-
tients that experienced vivid dreams, except one, had
them by second week of efavirenz treatment. Only 25%
of 115 had persistent episodes of vivid dreams until
week 12. Insomnia and sleepwalking were reported at
rates of 36.3% (n= 45) and 8.1% (n= 10) respectively.
About 89% (n= 40) of all patients that suffered from
efavirenz related insomnia had symptoms by week two
of treatment. 14 patients, among them 4 new cases,
complained of insomnia at week 12 of efavirenz treat-
ment. Almost all efavirenz related sleepwalking episodes
occurred within two weeks after initiation of treatment.
Only one patient reported sleepwalking after week two.
The commonest type of hallucination was the audio
form 75% (n= 47), followed by the visual 54% (n=34)
and tactile 7.9% (n=5) forms. Two and 21 persons ex-
perienced all or at least two forms of hallucinations
respectively. Like most of the other efavirenz neuro-
psychiatric symptoms, hallucinations occurred within
the first two weeks of treatment, with only 10, 3 and 1
experiencing the audio, visual and tactile forms respec-
tively, until week 12. The proportion of participants that
suffered efavirenz neuropsychiatric toxicity did not sig-
nificantly differ between women 76.8% (n=83) and men
69.4% (n=59) (p= 0.21), although overall, a tendency to
exhibit higher efavirenz plasma concentrations among
women at week-1 was observed (efavirenz plasma con-
centration female =2.8 mgl
-1versus efavirenz plasma con-
centration male = 2.2 mgl
-1, p=0.06). None of the study
participants discontinued their treatment regimen be-
cause of severe neuropsychological problems.
Efavirenz plasma concentrations and Rifampicin
cotreatment
Comparison of median efavirenz plasma concentrations
between the two treatment groups monitored at each
study time point is presented in Table 2. Significant dif-
ferences in the mean plasma efavirenz concentrations
between the two treatment groups (presence or absence
of rifampicin cotreatment) were observed only during
early initiation of efavirenz based HAART (at day-3 and
week-1). Then after no significant differences in the
mean plasma efavirenz concentration was observed.
Table 1 Baseline characteristics (demographics, measures of HIV disease and neuropsychiatric symptoms of HIV-only
and HIV-TB co-infected (Rifampicin treatment) study participants at initiation of ART
Baseline demographics and measures of HIV disease All participants (n=197) HIV- patients (n=59) HIV-TB patients (n=138) P-value
Proportion of female participants 109 (55.3) 40 (67.8) 69 (50.4) 0.02
Body weight at ART initiation / kg (±SD) 53.6± 10.1 56.5 ± 9.8 51.9± 10.0 0.015
Age / years (±SD) 33.8± 7.2 36.5 ± 6.1 32.7±7.4 0.003
Initial CD4 count (±SD) 97.2± 77.4 123.1± 63.7 86.2± 79.9 0.009
Log10. viral load (±SD) 4.95± 0.71 4.81± 0.73 5.02± 0.70 0.08
Baseline neuropsychiatric Symptoms 61 (31) 14 (23.7 ) 47 (34.1) 0.14
Sleep disorders 36 (18.3) 9(15.2) 27 (19.7) 0.46
Insomnia 21 (10.7) 6(10.2) 15(10.9) 0.88
Vivid dreams 11 (5.6) 4(6.9) 7(5.2) 0.66
Sleep walking 9 (4.6) 0(0.0) 9 (6.67) 0.04
Hallucinations 3(1.5) 1(1.7) 2(1.5) 0.9
Auditory 3(1.5) 1(1.7) 2(1.5) 0.9
Visual 0(0.0) 0(0.0) 0(0.0) -
Tactile 0(0.0) 0(0.0) 0(0.0) -
Cognitive disorder 46 (23.4) 9(15.2) 37 (27.0) 0.07
SD standard deviation.
Table 2 Comparison of median and interquartile range of
plasma efavirenz (EFV) concentrations (mg/L) between
HIV patients receiving EFV based HAART only and TB-HIV
coinfected patients receiving EFV based HAART with
rifampicin (RIF) based TB therapy
Treatment group p
EFV only EFV + RIF
N Median (IQR) N Median (IQR)
Day-3 57 2.48 (1.85-2.92) 107 1.85 (1.34-2.86) 0.02
week-1 53 2.37 (1.92-3.18) 57 1.80 (1.34-2.49) 0.01
week-2 53 2.21 (1.63-3.21) 100 1.94 (1.38-2.60) 0.21
week-4 49 2.45 (1.73-3.22) 103 1.87 (1.43-3.13) 0.48
week-6 38 2.37 (1.70-3.51) 86 1.89 (1.63-4.19) 0.93
week-8 50 2.41 (1.64-3.06) 118 1.82 (1.42-3.21) 0.40
week-12 44 2.41 (1.65-3.55) 101 2.04 (1.47-3.64) 0.69
Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7, 8
and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log
transformed efavirenz concentration was used using independent sample T-test.
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Comparison of plasma efavirenz concentrations be-
tween subjects who experienced neuropsychiatric disor-
ders during therapy and who did not is presented in
Table 3. There was significant association of having
higher plasma efavirenz concentrations with experience
of neuropsychiatric symptoms during efavirenz-based
therapy. We also compared plasma efavirenz concentra-
tions between the two treatment groups stratified by
neuropsychiatric symptoms during therapy (Table 4).
Interestingly among patients who experienced neuro-
psychiatric symptoms, the mean plasma efavirenz con-
centrations were comparable between the two treatment
groups and no significant differences were observed.
Coherent with lack of rifampicin cotreatment on efa-
virenz plasma concentrations, there was no significant dif-
ferences in the incidence of neuropsychiatric symptoms
between HIV patients (72%) receiving EFV based HAART
only versus TB-HIV coinfected patients (74%) receiving
EFV based HAART with rifampicin based anti-
tuberculosis therapy (chi square test p=0.73, odds ratio
1.126, 95% CI for odds ratio 0.56 to 2.25). Similarly logistic
regression reviled no significant association of rifampicin
cotreatment with Neuropsychiatric symptoms.
Effect of Pharmacogenetic variations
Efavirenz plasma concentrations were significantly
influenced by CYP2B6 genotypes at all study time
points. The number of people having efavirenz plasma
concentrations (>4 mg/l) increased from 14 on day 3 to
34 on day 84. Of the 14 and 34 people with high drug
concentrations 6 and 12 were among the 9 and 13
people homozygous for CYP2B6*6 respectively. No sig-
nificant effect of CYP2A6, NR1I3 rs3003596, CYP3A5
and ABCB1 c.3435C>T genotype on efavirenz plasma
concentrations was observed at all sampling occasions.
ABCB1 c.4036A>G genotype was associated with having
higher efavirenz plasma concentration at day-3, (p = 0.06)
and week-8 (p=0.04). Effect of CYP2B6*11 genotype on
efavirenz plasma concentration was observed at day-3
(p=0.07), week-2 (p=0.10) and week-4 (p=0.01).
Distribution of CYP2B6, CYP2A6, CYP3A5, ABCB1
and NR1I3 genotype and allele frequency between pa-
tients who devolved neuropsychiatric symptoms and
who did not during efavirenz treatment is presented in
Table 5. Neither ABCB1 (c.4046A>G and c.3435C>T),
CYP2A6 (*9 and *17) genotypes or the number of func-
tional alleles in CYP3A5*1 examined in this study were
related to neuropsychiatric toxicity. There was a ten-
dency of CYP2B6*6 genotype association with higher in-
cidence of having vivid dream (p=0.05), insomnia
(p=0.19) and tactile hallucination (p=0.09) at week-2.
Kaplan–Meier curves to estimate cumulative hazard for
the development of efavirenz-based highly active anti-
retroviral related neuropsychiatric symptoms during 12
weeks follow-up period between the different CYP2B6
genotype groups is presented in Figure 1. The propor-
tion of patients with CYP2B6*6/*6 genotype was much
higher (9.5%) among those with over all neuropsychiatric
disorders compared to those without (2%). Almost all
subjects with CYP2B6*6/*6 genotype except one experi-
enced neuropsychiatric disorders. There was a tendency
(p=0.06) of associations between NR1I3 rs3003596CT
genotype and neuropsychiatric symptoms (Table 5) but
the difference was observed mainly between homozy-
gous TT versus heterozygous CT genotype groups. Pro-
portion of subject homozygous for rs3003596 C variant
allele that is associated with low efavirenz plasma con-
centrations [20], were much higher (43.5%) among pa-
tients without neuropsychiatric symptoms compared
those who experienced such symptom (24.3%). Univari-
ate logistic regression analysis was done using each
genotype, sex and treatment group as independent pre-
dictors. CYP2B6*6 genotype was associated with vivid
dreams (p=0.05), sleepwalking (p=0.11), insomnia
(p=0.19) and tactile hallucination (p=0.09). A tendency
of CYP2B6*6 (0.21), NR1I3 rs3003596CT (0.06) geno-
type and sex (0.07) to predict the overall neuropsychi-
atric symptoms was observed. The predictive value did
not change significantly in the multivariate analyses
regression using backward conditional elimination and
no significant interaction between CYP2B6*6, NR1I3
rs3003596CT genotype and sex was observed.
Discussion
We examined the effects of plasma efavirenz concen-
trations, rifampicin cotreatment and pharmacogenetic
variations in five relevant genes on the incidence of
Table 3 Comparison of median and interquartile range
(IQR) of plasma efavirenz (EFV) concentrations (mg/L)
between patients who presented with any
neuropsychiatric disorders (Yes) and who did not (No)
during efavirenz based HAART among Ugandan HIV
patients with and without TB coinfection
Neuropsychiatric disorders p
No Yes
N Median (IQR) N Median (IQR)
Day-3 37 1.61 (1.37-2.29) 125 2.29 (1.52-2.92) 0.02
week-1 28 1.86 (1.43-2.55) 80 2.26 (1.67-3.1) 0.13
week-2 40 1.69 (1.32-2.15) 111 2.22 (1.41-3.21) 0.03
week-4 40 1.57 (1.31-2.25) 110 2.49 (1.58-3.57) 0.002
week-6 36 1.8 (1.42-2.61) 86 2.37 (1.66-4.25) 0.008
week-8 45 1.64 (1.36-2.81) 121 2.31 (1.53-3.21) 0.09
week-12 41 1.84 (1.45-2.57) 101 2.57 (1.68-4.19) 0.03
Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7,8
and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log
transformed efavirenz concentration was used using independent sample T-test.
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efavirenz related neuropsychiatric symptoms using sleep
disorders, hallucinations and cognition as its measure.
Our results indicate efavirenz plasma concentration as a
main predictor of neuropsychiatric symptoms in Ugandan
HIV patients receiving efavirenz based ART, a finding that
is consistent with previous reports from other populations
[28,34,42]. Efavirenz plasma concentrations were pre-
dicted by CYP2B6 genotypes at all study time points.
Though not statistically significant, we observed a ten-
dency of CYP2B6*6 genotype to be associated with rela-
tively higher incidence of sleep disorder and hallucination
by second week of initiation of therapy. The cumulative
hazards for the incidence of neuropsychiatric symptoms
were relatively higher in CYP2B6*6 genotypes (Figure 1).
Our result indicates that neither genetic polymorphism of
CYP3A5 and ABCB1 (c.4036 A/G and C3435T), CYP2A6
(*9 and *17) nor rifampicin co-treatment are significantly
correlated to efavirenz associated neuropsychiatric symp-
toms. We observed a tendency of NR1I3 rs3003596CT
genotype and sex to be associated with neuropsychi-
atric symptoms. This study is one of the few that have
examined efavirenz related neuropsychiatric toxicity
during rifampicin treatment in an African context
where HIV/TB co-infection and CYP2B6 genetic vari-
ation are most prevalent.
HIV infection is characterized by acquired impairment
in cognitive functioning, disturbances in memory, atten-
tion and processing speed [47]. It is important to note
that HIV/TB co infected patients are usually very ill and
hence their performance on cognitive tests may in part
be influenced by their physical wellbeing. Interestingly
one third of the study participants experienced neuro-
psychiatric symptoms, mainly cognitive disordered at
baseline, which improved later during ART. Our result
is supporting the evidence that HAART can improve the
cognitive dysfunction [48,49].
On the other hand other neuropsychiatric symptoms
associated with efavirenz therapy are recognized as a
major cause of non-adherence [13]. Clinical studies have
shown a high incidence of psychiatric effects among
HIV patients being treated with efavirenz, ranging from
61% to 90% [10-12]. Similarly in the present study, 73%
of the patients experienced neuropsychiatric symptoms
during the initial twelve weeks of efavirenz treatment.
Sleep disorders 60.5% were commonest followed by hal-
lucination 30.7%.
Notable however, is the lack of any significant differ-
ences in the incidence of efavirenz related neuropsychi-
atric symptoms between the two treatment groups even at
week two. Efavirenz product information indicates the
possibility of 20% and 26% reduction in Cmax and AUC
respectively, upon co-treatment with rifampicin [50].
Therefore rifampicin co-treatment is anticipated to lower
plasma efavirenz concentration and hence lower incidence
of neuropsychiatric symptoms among patient receiving
concomitant therapy. But effect of rifampicin on efavirenz
pharmacokinetics varies between populations. In the
present study effect of rifampicin cotreatment on plasma
efavirenz concentration was observed during the first
week of efavirenz initiation. Then after there was no sig-
nificant difference in the mean plasma efavirenz concen-
tration between patients receiving efavirenz with or
without rifampicin (Table 2). Coherent with this, we found
comparable efavirenz related neuropsychiatric toxicity
profiles among patients treated with or without rifampicin
based anti-tuberculosis therapy, which is similar to other
studies [51,52]. This finding is plausibly explained by simi-
lar efavirenz concentrations exhibited by patients in the
two treatment groups. Similar to our finding, several stu-
dies mainly in black and Asian populations, reported in-
significant effect of rifampicin on efavirenz plasma
concentration or even paradoxically increased efavirenz
Table 4 Comparison of median and interquartile range of plasma efavirenz (EFV) concentrations (mg/L) between
patients treated with EFV based HAART only (EFV only) versus TB-HIV coinfected patients treated with EFV based
HAART plus RIF based TB therapy (EFV + RIF) stratified by observed neuropsychiatric symptoms during therapy (Yes)
and who did not (No) during therapy
Neuropsychiatric disorders (No) Neuropsychiatric disorders (Yes)
EFV only EFV + RIF EFV only EFV + RIF
N Median (IQR) N Median (IQR) N Median (IQR) N Median (IQR)
Day-3 15 2.29 (1.41-2.88) 22 1.48 (1.15-1.88) 41 2.6 (2.09-2.94) 84 1.97 (1.38-2.91)
week-1 13 2.25 (1.84-2.69) 15 1.53 (1.28-1.97) 39 2.47 (2.09-3.23) 41 1.9 (1.34-2.61)
week-2 15 1.9 (1.27-2.3) 25 1.66 (1.36-2.11) 37 2.51 (1.84-3.43) 74 2.05 (1.4-2.67)
week-4 12 1.64 (1.46-2.43) 28 1.57 (1.19-2.17) 36 2.65 (2.05-3.56) 74 2.37 (1.55-3.57)
week-6 12 2.11 (1.46-3.41) 24 1.77 (1.37-2.02) 25 2.43 (1.94-3.51) 61 2.17 (1.66-4.63)
week-8 14 1.69 (1.41-2.49) 31 1.56 (1.34-3.05) 35 2.48 (2.23-3.13) 86 1.91 (1.48-3.22)
week-12 12 1.86 (1.45-2.26) 29 1.84 (1.45-2.7) 31 2.61 (2.04-4.09) 70 2.29 (1.56-4.45)
No significant difference in EFV concentrations between treatment groups was observed.
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concentration during rifampicin cotreatment [32,53-58].
Anti-TB drug adverse drug reactions have previously been
reported to have significant psychological effects on pa-
tients [36,37,59]. This study however demonstrates that
even with similar efavirenz plasma concentrations in both
treatment groups, neuropsychiatric symptoms did not dif-
fer implying that anti-TB treatment related neuropsychi-
atric effects may not be significant among Ugandan HIV
patients treated with efavirenz based regimens.
While this study demonstrates influence of CYP2B6
genotype on efavirenz plasma concentrations which pre-
dicted neuropsychiatric toxicity, we did not observe a direct
significant relationship between genotypes and neuro-
psychiatric toxicity but rather a tendency. All patients
homozygous for CYP2B6*6 allele, except one experienced
neuropsychiatric symptoms. Previous studies demonstrated
association of CYP2B6*6 with early discontinuation of
efavirenz-containing regimens mainly due to neurotoxicity
[41,60,61] whereas others failed to demonstrate direct asso-
ciations between CYP2B6 genotypes. Similar to our finding
a recent study in South African population reported a
strong association of efavirenz plasma concentration and a
tendency of CYP2B6*6 genotype with risk of developing
neuropsychiatric symptoms [42]. Our findings reveal indir-
ect association of CYP2B6 genotype with efavirenz related
neuropsychiatric disorders, indicating the need for more
association studies with larger sample size and power. On
the other hand, even with reported involvement of
p-glycoprotein in the drugs oral absorption and cerebral
spinal fluid concentrations, polymorphism of ABCB1 at
neither c.4036 A/G (rs3842) nor c.3435C/T was associated
with efavirenz neuropsychiatric toxicity, although a ten-
dency to influence day 3 efavirenz concentrations and sig-
nificant effect on week-8 by c.4036 A/G (rs3843) was
observed. Similarly no effect of CYP2B6*11 genotype on
neuropsychiatric symptoms was observed despites its asso-
ciation with efavirenz plasma concentration at day-3, week-
Table 5 Genotype and allele frequency distributions
among patients with or without neuropsychiatric
disorders during efavirenz based HAART
Genotype Neuropsychiatric disorders p
valueNo Yes
n % n %
CYP2B6*6 *1/*1 21 42 61 44.5 0.16
*1/*6 28 56 63 46
*6/*6 1 2 13 9.5
CYP2B6*11 *1/*1 41 82 111 78.2 0.17
*1/*11 8 16 31 21.8
*11/*11 1 2 0 0
CYP2A6*9 *1/*1 39 84.8 98 79.7 0.51
*1/*9 7 15.2 22 17.9
*9/*9 0 0 3 2.4
CYP2A6*17 *1/*1 38 90.5 104 83.9 0.3
*1/*17 3 7.1 19 15.3
*17/*17 1 2.4 1 0.8
No. of CYP3A5*1 allelesa zero 15 30 31 21.8 0.48
One 24 48 79 55.6
Two 11 22 32 22.5
ABCB1 (rs3842 *0/*0 29 63 87 65.4 0.95
*0/*1 16 34.8 43 32.3
*1/*1 1 2.2 3 2.3
ABCB1 c.3435C/T CC 37 74 109 77.9 0.68
CT 13 26 30 21.4
TT 0 0 1 0.7
NR1I3 rs3003569CT TT 10 21.7 29 23 0.06
TC 16 34.8 65 51.6





CYP2B6*6 30 32.5 0.21
CYP2B6*11 10 10.9 0.78
CYP2A6*9 7.61 11.38 0.31
CYP2A6*17 5.95 8.46 0.55
No. of CYP3A5*1 allele 46 50.4 0.56
ABCB1 rs3842 19.6 18.4 0.80
ABCB1 c.3435T 13 11.4 0.67
NR1I3 rs3003569 T 39.1 48.8 0.11
P value from binary logistic regression is presented.
a Haplotype analyses indicate no linkage between CYP3A5 SNPs thus subjects
were grouped based on number of functional CYP3A5 allele (CYP3A5*1) for
statistical analysis.
Figure 1 Kaplan–Meier curves indicating cumulative hazard for
the development of efavirenz-based highly active antiretroviral
therapy associated neuropsychiatric symptoms between the
different CYP2B6 genotype groups during 12 weeks in
Ugandan HIV patients.
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2 and week-4. The observed allele frequency of CYP2B6*11
and ABCB1 c.4036G alleles is lower than CYP2B6*6 al-
lele in Ugandan population and hence our study sample
size may lack adequate power to determine the actual
effect size and hence future studies with larger sample
size are required.
Current HIV treatment guidelines recommend imme-
diate initiation of ART in HIV patients diagnosed with
TB co-infection. Based on the endemicity of TB-HIV co-
infection, there is an anticipated increase in patients
concomitantly treated with efavirenz and rifampicin par-
ticularly in sub-Saharan Africa. The findings of this
study, which on one hand allay concerns of possible
pooled neuropsychiatric effects of efavirenz and anti-TB
drug related adverse drug reactions [36,37,59], are in
synchrony with periods of adaption of both CDC and
WHO guidelines by Uganda and other countries within
the African region. Our study may have important cli-
nical implications indicating no effect of concomitant
rifampicin therapy in HIV patients with respect to
efavirenz associated CNS toxicity. Ideally, neuropsychi-
atric toxicity should be assessed against CSF efavirenz
concentrations, which was not possible to do in the
present study. However, results of this study indicate the
relationship between CYP2B6 and ABCB1 genetic poly-
morphisms with efavirenz plasma concentrations.
Conclusion
Efavirenz related neuropsychiatric symptoms are frequent
and common among Ugandan HIV patients receiving
ART. Having higher plasma efavirenz concentration,
which is predicted by CYP2B6 genotype, significantly
increases the likelihood of developing neuropsychiatric
symptoms in HIV patients. Therapeutic drug monitoring
or CYP2B6 genotyping practice in HIV clinics during early
initiation of efavirenz therapy is encouraged to identify
patients susceptible for neuropsychiatric disorders for
optimal dosage adjustment. The finding of similar
efavirenz concentrations and neuropsychiatric toxicity
profiles in recipients of efavirenz with rifampicin or
without rifampicin encourages concomitant clinical use
of the two drugs among HIV/TB patients in Uganda
and similar populations.
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